Melanoma is a form of cancer that begins in melanocytes (cells that make the pigment melanin). It may begin in a mole (skin melanoma), but can also begin in other pigmented tissues, such as in the eye or in the intestines.
A potential immunotherapy method for treating metastatic melanoma is adoptive cell therapy (ACT). The method, which utilizes the use of immune cells extracted from the patient’s own tumors, could offer cancer patients new options for treatment by eschewing radiation therapies and harsh chemotherapy drugs.
According to a study conducted by UCLA, patients with advanced melanoma responded differently to PD-1 checkpoint blockade immunotherapy depending on a variety of variables, including whether or not they had previously received CTLA-4 blockade, another type of immunotherapy.
Even as pancreatic cancer treatments advance, only around 9% of patients live beyond five years. Scientists have failed to identify genetic distinctions that explain why some patients live for a long time and others do not, so they have moved their emphasis to the gut microbiome.
Cancer that has spread to areas like the lungs can apply the brakes to a natural pathway that should recruit killer T cells directly to where it has metastasized, scientists report.
In the future, vaccines may be delivered with a puff of air rather than a needle, according to the promising results of new research presented at a meeting of the American Chemistry Society this March.
Custom-made to attack cancer cells, CAR T-cell therapies have opened a new era in the treatment of human cancers, particularly, in hematologic malignancies.
Most immunotherapies that aim to increase T cell activity are ineffective in treating estrogen receptor-positive (ER+) breast cancer. A new study of invasive ER+ breast cancers led by researchers at the University of Pittsburgh School of Medicine implies that targeting a different type of immune cell called macrophages may be a more effective approach.
Most immunotherapies, which aim to boost T cell activity, work poorly in treating estrogen receptor-positive (ER+) breast cancer.
TALAPRO-2, a study led by Neeraj Agarwal, MD, FASCO, demonstrated that using TALZENNA, in combination with XTANDI, may reduce the risk of disease progression or death by 37%.
In a Phase II trial led by researchers from The University of Texas MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant, or pre-surgical, combination of nivolumab plus platinum-based chemotherapy, resulted in a major pathologic response (MPR) in half of all treated patients with early-stage, resectable non-small cell lung cancer (NSCLC).
Immunotherapy is an effective form of treatment for various types of cancer. However, its effect on pancreatic cancer is restricted and varies between men and women. Karolinska Institutet scientists have observed a possible explanation for this gender difference.
For the first time, a research team has identified and analyzed the steps by which immune cells "see" and respond to cancer cells, providing insights into reasons some treatments may be effective for certain patients but not others.
Immunotherapy has transformed cancer care. In advanced melanoma, for example, the most fatal form of skin cancer, the five-year survival rate has risen from less than 10% to more than 50% since immunotherapy was introduced in 2011.
Thanks to a new prognostic method for detecting cancers including cancer of the large intestine, doctors could provide clearer disease prognoses and predict which patients will respond best to immunotherapy.
Immunotherapy -; drug treatment that stimulates the immune system to attack tumors -; works well against some types of cancer, but it has shown mixed success against lung cancer.
A new way to significantly increase the potency of almost any vaccine has been developed by researchers from the International Institute for Nanotechnology at Northwestern University.
Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
Cancer experts have tried, sometimes unsuccessfully, to use the total number of mutations in a tumor, called the tumor mutation burden (TMB), to predict a patient's response to immunotherapy.
In two distinct studies, scientists show how synthetic biology can be used to address a challenging problem in cancer immunotherapy: the way immunotherapy-related approaches focused on the short-term killing of tumor cells could fail to eradicate tumors because tumor growth occurs on longer timescales.
After analyzing data from a public repository, CD4-T, CD8-T cells, and Treg cells, a team of researchers led by bioinformatics Mabel Vidal from the University of Concepcion and working with researchers from MELISA Institute and other academic institutions discovered a distinctive genetic signature among subsets of infiltrating T cells of various types of cancer.